Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
Kazunari TanakaKunihiko TsujiAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiToru IshikawaKazuto TajiriHironori OchiHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataAtsushi NaganumaHisashi KosakaTomomitsu MatonoHidekatsu KurodaYutaka YataHideko OhamaFujimasa TadaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiKeisuke YokohamaHiroki NishikawaMichitaka ImaiYohei KoizumiShinichiro NakamuraHiroko IijimaMasaki KaiboriYoichi HiasaTakashi Kumadanull nullPublished in: Cancers (2023)
The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as first-line treatment.